Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $90.16 USD
Change Today -2.26 / -2.45%
Volume 94.9K
LGND On Other Exchanges
Symbol
Exchange
NASDAQ GM
OTC US
Frankfurt
OTC US
OTC US
As of 12:26 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals (LGND) Snapshot

Open
$93.21
Previous Close
$92.42
Day High
$93.99
Day Low
$89.98
52 Week High
08/5/15 - $112.40
52 Week Low
10/9/14 - $41.99
Market Cap
1.8B
Average Volume 10 Days
423.9K
EPS TTM
$1.12
Shares Outstanding
19.9M
EX-Date
04/3/07
P/E TM
80.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGAND PHARMACEUTICALS (LGND)

ligand pharmaceuticals (LGND) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals (LGND) Details

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; and Captisol-enabled Noxafil-IV, a formulation of posaconazole for intravenous (IV) use. Its late-stage development programs include Captisol-enabled Melphalan IV, MK-8931 Beta-Secretase Inhibitor, Captisol-enabled SAGE-547, Sparsentan, Captisol-enabled Delafloxacin-IV, Captisol-enabled Carbamazepine-IV, IRAK4 Inhibitor Program, LTP Technology with Omega-3 Fatty Acids, Biologic Therapeutics Platform, Captisol-enabled Topiramate IV, Lasofoxifene, and Captisol-enabled Lamotrigine IV. The company’s internal product development programs include Glucagon Receptor Antagonist Program, Oral Human Granulocyte Colony Stimulating Factor Program, LTP Platform, Kinase Inhibitors, HepDirect HCV Inhibitor Program, and other programs. Its therapies in development portfolio addresses the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. Ligand Pharmaceuticals Incorporated has alliances with GlaxoSmithKline, Amgen, Inc., Merck, Pfizer, Baxter International, and Eli Lilly and Co. The company was founded in 1987 and is headquartered in La Jolla, California.

19 Employees
Last Reported Date: 02/23/15
Founded in 1987

ligand pharmaceuticals (LGND) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $510.2K
President and Chief Operating Officer
Total Annual Compensation: $375.4K
Vice President, General Counsel and Secretary
Total Annual Compensation: $288.9K
Compensation as of Fiscal Year 2014.

ligand pharmaceuticals (LGND) Key Developments

Ligand Pharmaceuticals Incorporated's Revolade® Receives EU Approval as Therapy for Patients with Severe Aplastic Anemia

Ligand Pharmaceuticals Incorporated announced the European Commission has approved Revolade® (eltrombopag), a Novartis product, for the treatment of adults with severe aplastic anemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem cell transplant. The approval is based on the results of a pivotal open-label Phase 2 study (ELT112523) and two supporting Phase 2 studies (ELT116826 and ELT116643) conducted by the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH). The pivotal study demonstrated a hematologic response (40%) in SAA patients treated with Revolade who had an insufficient response to IST. The most common adverse reactions (=20%) in the pivotal single-arm study of 43 patients were nausea, fatigue, cough, transaminase increased, diarrhea, and headache. The European Commission approval applies to all 28 EU member states plus Iceland, Norway and Liechtenstein. In the single-arm, single-center, open-label Phase 2 study (NCT00922883), eltrombopag was evaluated in 43 patients with SAA who have had an insufficient response to at least one prior IST and who had a platelet count =30 x 109/L. At baseline, the median platelet count was 20 x 109/L, hemoglobin was 8.4 g/dL, absolute neutrophil count (ANC) was 0.58 x 109/L, and absolute reticulocyte count was 24.3 x 109/L. The treated population had a median age of 45 years (range 17 to 77 years) and 56% were male. The majority of patients (84%) received at least two prior immunosuppressive therapies. Eltrombopag was administered at an initial dose of 50 mg once daily for two weeks and increased over two-week periods up to a maximum dose of 150 mg once daily. The primary endpoint was hematologic response, which was initially assessed after 12 weeks of treatment with eltrombopag. Treatment was discontinued after 16 weeks if no hematologic response was observed. Additional efficacy assessments included median duration of response in months.

Ligand Pharmaceuticals Incorporated Appoints Matthew Korenberg as Vice President, Finance and Chief Financial Officer

Ligand Pharmaceuticals Incorporated announced the appointment of Matthew Korenberg as Vice President, Finance and Chief Financial Officer. Mr. Korenberg is expected to join Ligand’s management team on August 6, 2015. Mr. Korenberg joins Ligand from NeuroCircuit Therapeutics, where he was founder and Chief Executive Officer.

Ligand Pharmaceuticals Incorporated Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter, Second Half and Revises Earnings Guidance for the Full Year 2015

Ligand Pharmaceuticals Incorporated announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $18,418,000 compared to $10,608,000 for the same period a year ago. Gains from operations were $4,365,000 against $1,358,000 a year ago. Net income was $23,564,000 or $1.11 per diluted share against $1,592,000 or $0.07 per diluted share a year ago. Adjusted net income was $38,481,000 or $1.81 per diluted share against $5,168,000 or $0.24 per diluted share a year ago. The company generated operating cash of $17.6 million, a significant increase over $6.6 million of operating cash generated in the second quarter of 2014. The significant increase on operating cash flow illustrates the leverage in Ligand's business model of growing royalties and top line revenues combined with a low-cost infrastructure. The primary driver of the increase in adjusted earnings was due to the impact of the Viking Therapeutics IPO. For the six months, the company reported net sales of $33,020,000 compared to $26,566,000 for the same period a year ago. Gains from operations were $7,715,000 against $6,458,000 a year ago. Net income was $24,318,000 or $1.16 per diluted share against $3,688,000 or $0.17 per diluted share a year ago. Adjusted net income was $45,362,000 or $2.16 per diluted share against $12,511,000 or $0.57 per diluted share a year ago. The company reaffirms earnings guidance for full year 2015. For the year, the company expects total revenues to be between $81.0 million and $83.0 million, and adjusted earnings per diluted share to be between $3.45 and $3.50. The adjusted earnings per share guidance for both the full year and second half of 2015 exclude changes in contingent liabilities, mark-to-market adjustment for investments owed to licensors, noncash stock-based compensation expense, equity and net losses of Viking and noncash debt-related costs. The company will continue to pay cash taxes of less than 5%. For the second half of 2015, the company expects total revenues to be between $48.0 million and $50.0 million, and adjusted earnings per diluted share to be between $1.29 and $1.34. Approximately one-third of the second half revenue and earnings outlook is projected for the third quarter.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGND:US $90.16 USD -2.26

LGND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.40 USD +0.1638
Allergan plc $300.95 USD +1.34
Johnson & Johnson $93.17 USD -0.18
Pfizer Inc $32.04 USD +0.07
Valeant Pharmaceuticals International Inc C$303.94 CAD -4.06
View Industry Companies
 

Industry Analysis

LGND

Industry Average

Valuation LGND Industry Range
Price/Earnings 57.0x
Price/Sales 24.6x
Price/Book 25.4x
Price/Cash Flow 53.8x
TEV/Sales 19.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.